Last reviewed · How we verify

Hep B + Pentabio (registered) — Competitive Intelligence Brief

Hep B + Pentabio (registered) (Hep B + Pentabio (registered)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination vaccine. Area: Immunology / Infectious Disease Prevention.

phase 3 Combination vaccine Immunology / Infectious Disease Prevention Biologic Live · refreshed every 30 min

Target snapshot

Hep B + Pentabio (registered) (Hep B + Pentabio (registered)) — PT Bio Farma. Hep B + Pentabio is a combination vaccine that provides immunization against hepatitis B and five other infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b) by stimulating adaptive immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hep B + Pentabio (registered) TARGET Hep B + Pentabio (registered) PT Bio Farma phase 3 Combination vaccine
Boostrix ® Polio Boostrix ® Polio GlaxoSmithKline marketed Combination vaccine
Boostrix®-IPV combination vaccine Boostrix®-IPV combination vaccine University of Oxford marketed combination vaccine
Pentacel (DPTaP+Hib) Pentacel (DPTaP+Hib) The Hospital for Sick Children marketed Combination vaccine
Boostrix IPV infant whole Pertussis Boostrix IPV infant whole Pertussis London School of Hygiene and Tropical Medicine marketed Combination vaccine
Healive+Healive Healive+Healive Sinovac Biotech Co., Ltd marketed Combination vaccine Hepatitis A virus antigen; Hepatitis B surface antigen (HBsAg)
Infanrix IPV Infanrix IPV GlaxoSmithKline marketed combination vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination vaccine class)

  1. GlaxoSmithKline · 22 drugs in this class
  2. Sanofi Pasteur, a Sanofi Company · 8 drugs in this class
  3. Serum Institute of India Pvt. Ltd. · 3 drugs in this class
  4. Merck Sharp & Dohme LLC · 3 drugs in this class
  5. Sanofi · 3 drugs in this class
  6. PT Bio Farma · 2 drugs in this class
  7. Statens Serum Institut · 2 drugs in this class
  8. China National Biotec Group Company Limited · 2 drugs in this class
  9. Tanabe Pharma Corporation · 2 drugs in this class
  10. The Hospital for Sick Children · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hep B + Pentabio (registered) — Competitive Intelligence Brief. https://druglandscape.com/ci/hep-b-pentabio-registered. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing